618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I

Integrative clinical and molecular analysis of outcome in elderly African ancestry Acute Myeloid Leukemia

AI derived prediction of response and relapse to venetoclax plus hypomethylating agent based therapy in Acute Myeloid Leukemia

Impact of cancer and therapy on the epigenetic landscapes of normal cells Describing a novel biomarker in survivorship

Prognostic impact of co occurring mutations in NPM1 mutated Acute Myeloid Leukemia

Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia

Characteristics genomic landscape and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia AML

Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia AML associated with decreased inflammatory response patterns and favorable outcomes in young male patients pts

Clonal evolution of pediatric Acute Myeloid Leukemia

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3 ITD negative AML A subanalysis from the pethema quiwi trial

Clinical characteristics and comutational landscape of CSF3R mutations in acute myeloid leukemia

Apcin derived CDC20 inhibitors synergize with microtubule disruptors to induce mitotic catastrophe in acute leukemias

Multi omics integration reveals therapeutic vulnerabilities and immune microenvironment subtypes in Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia transformed from chronic myelomonocytic leukemia is strongly resistant to venetoclax but demonstrates sensitivity to anti GM CSF lenzilumab immunotherapy

TGF ß regulates CD123 and chemotherapy resistance in Acute Myeloid Leukemia stem cells

DNMT3A NPM1 and FLT3 ITD triple mutated AML has a favorable prognosis in the era of FLT3 inhibitors

Genetic risk model to predict outcomes for AML treated with HMA and venetoclax

A perturb seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A rearranged AML

Fus ERG fusion represents adverse plus risk group in AML patients Evidence from a registry based matched cohort Study

TP53 mutated AML and treatment outcomes in the era of hypomethylating agent venetoclax therapy

Anti TIM3 with hypomethylating agent revives NK and cytotoxic CD4 T cell activity in patients with AML or MDS

FLT3 ITD mutation promotes leukemic differentiation toward an immature cytotoxic stage

NUP98 NSD1 fusion is associated with poor outcomes in Acute Myeloid Leukemia regardless of co occurring mutations and treatment regimen

Novel epitranscriptomic biomarker discovery through ensemble analysis and multi omics integration in AML

High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

The synonymous IDH1 p Gly105Gly rs11554137 variant associates with AML post transplant relapse via aberrant signal transduction pathways

Adult Acute Myeloid Leukemia with fus ERG fusion A national retrospective multi center study

Distinct transcriptomic signatures in non hispanic black AML patients with NPM1 mutations reveal potential drivers of poor prognosis

Longitudinal single cell spatial proteomics reveals predictive immune and stem cell signatures in Relapsed Refractory AML

New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein

Prognosis of FLT3 ligand level in newly diagnosed FLT3 ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Multi omics unveils ER stress driven pDC like leukemia stem cells in pDC AML

Acute myeloid leukemia with 4q12 rearrangements does not involve pdgfra